Data Byte: AbbVie’s oral JAK takes the lead in coming competition for Dupixent in atopic dermatitis

Phase III data for coming entrants to the atopic dermatitis market show Rinvoq upadacitinib from AbbVie Inc. (NYSE:ABBV) has the edge in efficacy, compared with three other Phase III programs and the marketed therapy Dupixent dupilumab.

The oral JAK-1 inhibitor has produced response rates of up to 80% on the endpoint of ≥75% improvement in Eczema Area Severity Index (EASI 75) and up to a 62% response rate for Investigator’s Global Assessment (IGA) for atopic dermatitis of 0/1; both were co-primary endpoints in Rinvoq’s and most others’ Phase III trials...